G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
4.090
-0.130 (-3.08%)
At close: May 24, 2024, 4:00 PM
4.100
+0.010 (0.24%)
After-hours: May 24, 2024, 6:45 PM EDT

Company Description

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.

The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.

The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications.

G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc.
G1 Therapeutics logo
Country United States
Founded 2008
IPO Date May 17, 2017
Industry Biotechnology
Sector Healthcare
Employees 100
CEO John E. Bailey Jr.

Contact Details

Address:
700 Park Offices Drive, Suite 200
Research Triangle Park, North Carolina 27709
United States
Phone 919-213-9835
Website g1therapeutics.com

Stock Details

Ticker Symbol GTHX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001560241
CUSIP Number 3621LQ109
ISIN Number US3621LQ1099
Employer ID 26-3648180
SIC Code 2834

Key Executives

Name Position
John E. Bailey Jr. Chief Executive Officer, President and Director
Mark Avagliano Chief Business Officer
John W. Umstead V Chief Financial Officer
Terry L. Murdock Chief Operating Officer
William C. Roberts Vice President of Investor Relations and Corporate Communications
Monica R. Thomas Chief Legal and People Officer
Evan Hicks M.B.A. Vice President of Marketing
Dr. Rajesh K. Malik Ch.B., M.B., M.D. Chief Medical Officer
Andrew Perry Chief Commercial Officer
Jeff Macdonald Senior Director of Investor Relations and Corporate Communications

Latest SEC Filings

Date Type Title
May 1, 2024 10-Q Quarterly Report
May 1, 2024 8-K Current Report
Apr 25, 2024 ARS Filing
Apr 25, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2024 DEF 14A Other definitive proxy statements
Apr 12, 2024 PRE 14A Other preliminary proxy statements
Apr 9, 2024 144 Filing
Mar 22, 2024 8-K Current Report
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report